Bladder cancer biomarker screening based on non-targeted urine metabolomics
Purpose Bladder cancer is one of the most common malignancies of the urinary system, and its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury and infection. This study aims to use non-targeted metabolomics methods to screen for metabolites that are signifi...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2022, Vol.54 (1), p.23-29 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 29 |
|---|---|
| container_issue | 1 |
| container_start_page | 23 |
| container_title | International urology and nephrology |
| container_volume | 54 |
| creator | Li, Jinkun Cheng, Bisheng Xie, Hongbing Zhan, Chuanchuan Li, Shipeng Bai, Peiming |
| description | Purpose
Bladder cancer is one of the most common malignancies of the urinary system, and its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury and infection. This study aims to use non-targeted metabolomics methods to screen for metabolites that are significantly different between the urine of bladder cancer patients and cancer-free controls.
Methods
In this study, liquid chromatography–mass spectrometry was used to analyze the urine of bladder cancer patients (
n
= 57) and the cancer-free controls (
n
= 38) by non-targeted metabolomic analysis and metabolite identification.
Results
The results showed that there were significant differences in the expression of 27 metabolites between bladder cancer patients and the cancer-free controls.
Conclusion
In the multivariate statistical analysis of this study, the urinary metabolic profile data of bladder cancer patients were analyzed, and the receiver operating characteristic curve analysis showed that it is possible to perform non-invasive clinical diagnoses of bladder cancer through these candidate biomarkers. |
| doi_str_mv | 10.1007/s11255-021-03080-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2605230037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2616788274</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-441f76f20a8b611fee1e862a1b6df6c247dddbd05668f02cf666dbee2cde4dd73</originalsourceid><addsrcrecordid>eNp9kE1PxCAQhonR6PrxBzyYJl68oAO0FI-68SuaeNEzoTDddG1BoT3472VdPxIPngaYZ14mDyGHDE4ZQH2WGONVRYEzCgIUULlBZqyqBeWVKjfJLL8yyiQXO2Q3pSUAnCuAbbIjSlWB4PWM3F_2xjmMhTXe5tJ0YTDxJZ-SjYi-84uiMQldEXzhg6ejiQsc832KncdiwNE0oQ9DZ9M-2WpNn_Dgq-6R5-urp_ktfXi8uZtfPFBbsvORliVra9lyMKqRjLWIDJXkhjXStdLysnbONQ4qKVUL3LZSStcgcuuwdK4We-Rknfsaw9uEadRDlyz2vfEYpqS5hIoLALFCj_-gyzBFn7fLFJO1UrwuM8XXlI0hpYitfo1d1vCuGeiVar1WrbNq_alayzx09BU9NQO6n5FvtxkQayDlll9g_P37n9gP3zCJbw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616788274</pqid></control><display><type>article</type><title>Bladder cancer biomarker screening based on non-targeted urine metabolomics</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Li, Jinkun ; Cheng, Bisheng ; Xie, Hongbing ; Zhan, Chuanchuan ; Li, Shipeng ; Bai, Peiming</creator><creatorcontrib>Li, Jinkun ; Cheng, Bisheng ; Xie, Hongbing ; Zhan, Chuanchuan ; Li, Shipeng ; Bai, Peiming</creatorcontrib><description>Purpose
Bladder cancer is one of the most common malignancies of the urinary system, and its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury and infection. This study aims to use non-targeted metabolomics methods to screen for metabolites that are significantly different between the urine of bladder cancer patients and cancer-free controls.
Methods
In this study, liquid chromatography–mass spectrometry was used to analyze the urine of bladder cancer patients (
n
= 57) and the cancer-free controls (
n
= 38) by non-targeted metabolomic analysis and metabolite identification.
Results
The results showed that there were significant differences in the expression of 27 metabolites between bladder cancer patients and the cancer-free controls.
Conclusion
In the multivariate statistical analysis of this study, the urinary metabolic profile data of bladder cancer patients were analyzed, and the receiver operating characteristic curve analysis showed that it is possible to perform non-invasive clinical diagnoses of bladder cancer through these candidate biomarkers.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-021-03080-6</identifier><identifier>PMID: 34850327</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biomarkers ; Biomarkers, Tumor - metabolism ; Biomarkers, Tumor - urine ; Bladder cancer ; Cancer ; Early Detection of Cancer ; Humans ; Liquid chromatography ; Mass spectroscopy ; Medicine ; Medicine & Public Health ; Metabolites ; Metabolome ; Metabolomics ; Nephrology ; Patients ; Statistical analysis ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - metabolism ; Urinary Bladder Neoplasms - urine ; Urine ; Urology ; Urology - Original Paper</subject><ispartof>International urology and nephrology, 2022, Vol.54 (1), p.23-29</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature B.V.</rights><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-441f76f20a8b611fee1e862a1b6df6c247dddbd05668f02cf666dbee2cde4dd73</citedby><cites>FETCH-LOGICAL-c419t-441f76f20a8b611fee1e862a1b6df6c247dddbd05668f02cf666dbee2cde4dd73</cites><orcidid>0000-0003-4676-755X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-021-03080-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-021-03080-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34850327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jinkun</creatorcontrib><creatorcontrib>Cheng, Bisheng</creatorcontrib><creatorcontrib>Xie, Hongbing</creatorcontrib><creatorcontrib>Zhan, Chuanchuan</creatorcontrib><creatorcontrib>Li, Shipeng</creatorcontrib><creatorcontrib>Bai, Peiming</creatorcontrib><title>Bladder cancer biomarker screening based on non-targeted urine metabolomics</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Purpose
Bladder cancer is one of the most common malignancies of the urinary system, and its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury and infection. This study aims to use non-targeted metabolomics methods to screen for metabolites that are significantly different between the urine of bladder cancer patients and cancer-free controls.
Methods
In this study, liquid chromatography–mass spectrometry was used to analyze the urine of bladder cancer patients (
n
= 57) and the cancer-free controls (
n
= 38) by non-targeted metabolomic analysis and metabolite identification.
Results
The results showed that there were significant differences in the expression of 27 metabolites between bladder cancer patients and the cancer-free controls.
Conclusion
In the multivariate statistical analysis of this study, the urinary metabolic profile data of bladder cancer patients were analyzed, and the receiver operating characteristic curve analysis showed that it is possible to perform non-invasive clinical diagnoses of bladder cancer through these candidate biomarkers.</description><subject>Biomarkers</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomarkers, Tumor - urine</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Early Detection of Cancer</subject><subject>Humans</subject><subject>Liquid chromatography</subject><subject>Mass spectroscopy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolites</subject><subject>Metabolome</subject><subject>Metabolomics</subject><subject>Nephrology</subject><subject>Patients</subject><subject>Statistical analysis</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>Urine</subject><subject>Urology</subject><subject>Urology - Original Paper</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kE1PxCAQhonR6PrxBzyYJl68oAO0FI-68SuaeNEzoTDddG1BoT3472VdPxIPngaYZ14mDyGHDE4ZQH2WGONVRYEzCgIUULlBZqyqBeWVKjfJLL8yyiQXO2Q3pSUAnCuAbbIjSlWB4PWM3F_2xjmMhTXe5tJ0YTDxJZ-SjYi-84uiMQldEXzhg6ejiQsc832KncdiwNE0oQ9DZ9M-2WpNn_Dgq-6R5-urp_ktfXi8uZtfPFBbsvORliVra9lyMKqRjLWIDJXkhjXStdLysnbONQ4qKVUL3LZSStcgcuuwdK4We-Rknfsaw9uEadRDlyz2vfEYpqS5hIoLALFCj_-gyzBFn7fLFJO1UrwuM8XXlI0hpYitfo1d1vCuGeiVar1WrbNq_alayzx09BU9NQO6n5FvtxkQayDlll9g_P37n9gP3zCJbw</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Li, Jinkun</creator><creator>Cheng, Bisheng</creator><creator>Xie, Hongbing</creator><creator>Zhan, Chuanchuan</creator><creator>Li, Shipeng</creator><creator>Bai, Peiming</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4676-755X</orcidid></search><sort><creationdate>2022</creationdate><title>Bladder cancer biomarker screening based on non-targeted urine metabolomics</title><author>Li, Jinkun ; Cheng, Bisheng ; Xie, Hongbing ; Zhan, Chuanchuan ; Li, Shipeng ; Bai, Peiming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-441f76f20a8b611fee1e862a1b6df6c247dddbd05668f02cf666dbee2cde4dd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomarkers, Tumor - urine</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Early Detection of Cancer</topic><topic>Humans</topic><topic>Liquid chromatography</topic><topic>Mass spectroscopy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolites</topic><topic>Metabolome</topic><topic>Metabolomics</topic><topic>Nephrology</topic><topic>Patients</topic><topic>Statistical analysis</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>Urine</topic><topic>Urology</topic><topic>Urology - Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Jinkun</creatorcontrib><creatorcontrib>Cheng, Bisheng</creatorcontrib><creatorcontrib>Xie, Hongbing</creatorcontrib><creatorcontrib>Zhan, Chuanchuan</creatorcontrib><creatorcontrib>Li, Shipeng</creatorcontrib><creatorcontrib>Bai, Peiming</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jinkun</au><au>Cheng, Bisheng</au><au>Xie, Hongbing</au><au>Zhan, Chuanchuan</au><au>Li, Shipeng</au><au>Bai, Peiming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bladder cancer biomarker screening based on non-targeted urine metabolomics</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2022</date><risdate>2022</risdate><volume>54</volume><issue>1</issue><spage>23</spage><epage>29</epage><pages>23-29</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>Purpose
Bladder cancer is one of the most common malignancies of the urinary system, and its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury and infection. This study aims to use non-targeted metabolomics methods to screen for metabolites that are significantly different between the urine of bladder cancer patients and cancer-free controls.
Methods
In this study, liquid chromatography–mass spectrometry was used to analyze the urine of bladder cancer patients (
n
= 57) and the cancer-free controls (
n
= 38) by non-targeted metabolomic analysis and metabolite identification.
Results
The results showed that there were significant differences in the expression of 27 metabolites between bladder cancer patients and the cancer-free controls.
Conclusion
In the multivariate statistical analysis of this study, the urinary metabolic profile data of bladder cancer patients were analyzed, and the receiver operating characteristic curve analysis showed that it is possible to perform non-invasive clinical diagnoses of bladder cancer through these candidate biomarkers.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>34850327</pmid><doi>10.1007/s11255-021-03080-6</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4676-755X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1623 |
| ispartof | International urology and nephrology, 2022, Vol.54 (1), p.23-29 |
| issn | 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2605230037 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Biomarkers Biomarkers, Tumor - metabolism Biomarkers, Tumor - urine Bladder cancer Cancer Early Detection of Cancer Humans Liquid chromatography Mass spectroscopy Medicine Medicine & Public Health Metabolites Metabolome Metabolomics Nephrology Patients Statistical analysis Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - urine Urine Urology Urology - Original Paper |
| title | Bladder cancer biomarker screening based on non-targeted urine metabolomics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A00%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bladder%20cancer%20biomarker%20screening%20based%20on%20non-targeted%20urine%20metabolomics&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Li,%20Jinkun&rft.date=2022&rft.volume=54&rft.issue=1&rft.spage=23&rft.epage=29&rft.pages=23-29&rft.issn=0301-1623&rft.eissn=1573-2584&rft_id=info:doi/10.1007/s11255-021-03080-6&rft_dat=%3Cproquest_cross%3E2616788274%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616788274&rft_id=info:pmid/34850327&rfr_iscdi=true |